Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMI-115 in Endometriosis-Associated Moderate to Severe Pain (Phase 3, China)
CTR20255175Phase 3Active
- Sponsor
- HopeMed
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of HMI-115 in endometriosis, sponsored by HopeMed. Started Mar 2026; status: active.
02
Drugs
HMI-115
03
Conditions
endometriosis
Beyond the preview
Go deeper on CTR20255175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255175.